Healio Gastroenterology Current Issue
The following articles appeared in the print edition of Healio Gastroenterology.
Table of Contents
- The Arrival of Biosimilar Therapies
-
- 7 IBD Studies Presented at ACG 2015
- Imaging Developments in Crohn's Disease David H. Bruining, MD
- FDA Grants Breakthrough Therapy Designation to Keytruda for Advanced Colorectal Cancer
- Harvoni Expands Dosing Recommendations
- Phase 2 Trial of Bertilimumab in UC Initiated
- Synthetic Biologics Receives U.S. Patent for Microbiome-Based Drug Candidate for IBS-C
- The Advent of Biosimilars: Experts Debate Concepts, Concerns
- The Patient with Abdominal Discomfort and Diarrhea
-
- ASCO: Expanded Genetic Testing Should be Standard for Metastatic Colorectal Cancer
- Experts Reach Consensus on Nutrition Recommendations at Nonprofit Summit
- Functional Dyspepsia Under-Recognized in Practice, Often Mislabeled GERD
- IBD Patients Accept Risks of Medical Therapies to Maintain Remission
- Judicious PPI Use Necessary to Avoid Serious Adverse Events
- Targeted Intervention Program Increases Colorectal Cancer Screening in NYC
- Gluten Peptides in Urine Correlate with Mucosal Damage in Celiac Disease
- Low-, High-Dose FMT Capsules Effective for Recurrent C. difficile Infection
-
- OpenBiome Develops FMT Pill for Recurrent C. difficile Infection
- GI Societies Share Consensus Principles with ABIM on Changes to MOC
- Harvoni Price ‘Maximizes’ Revenue, U.S. Senate Committee Investigation Concludes